Saturday 17 October 2026
Export KNSA’s income statement to Excel — free account
Kiniksa Pharmaceuticals International, plc
KNSA Healthcare Drug Manufacturers Specialty & Generic
Kiniksa Pharmaceuticals International, plc’s revenue for fiscal 2025 (year ended December 2025) was $677.6 million, up 60.1% from fiscal 2024. In the quarter to June 2026, revenue grew 55.4%, EPS grew 37.5% and free cash flow grew 66.6%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for five.
78.59
1.35
−1.69%
Follow KNSA
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | 13.04 | 5.01 | 10.30 | 10.30 | 7.36 | 10.29 | 16.56 | 17.82 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | 32.88 | 28.43 | 28.67 | 24.70 | 17.20 | 20.65 | 28.15 | 44.42 | |||||
| People | |||||||||||||||
| People | Employees | — | 47 | 111 | 137 | 168 | 215 | 220 | 297 | 315 | 366 | ||||
| Revenue/emp, $m | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.18 | 1.00 | 0.91 | 1.34 | 1.85 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | 39 | 220 | 270 | 423 | 678 | ||||
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 76.39 | 89.60 | 87.64 | 85.61 | 88.54 | |||||
| EBT | (24) | (65) | (103) | (164) | (156) | (157) | 11 | (17) | (36) | 89 | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (406.13) | 5.01 | (6.16) | (8.54) | 13.12 | |||||
| Net income | (24) | (65) | (103) | (162) | (161) | (158) | 183 | 14 | (43) | 59 | |||||
| Depreciation | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.56 | 3.17 | 3.86 | 5.93 | 9.13 | ||||
| Earnings | (91.61) | (35.84) | (3.49) | (2.99) | (2.61) | (2.30) | 2.64 | 0.20 | (0.60) | 0.80 | |||||
| Cash flow | (83.56) | (27.75) | (2.74) | (2.93) | (2.21) | (1.84) | 0.08 | 0.19 | 0.36 | 1.86 | |||||
| Capex | (0.01) | (0.04) | (0.18) | (0.06) | 0.00 | (0.30) | 0.00 | 0.00 | 0.00 | (0.02) | |||||
| Free cash flow | (83.57) | (27.78) | (2.92) | (2.99) | (2.21) | (2.14) | 0.08 | 0.19 | 0.36 | 1.84 | |||||
| Book value | 206.97 | 16.61 | 9.45 | 4.17 | 5.04 | 2.70 | 5.71 | 6.26 | 6.14 | 7.65 | |||||
| Shares, m | 0 | 2 | 30 | 54 | 62 | 69 | 69 | 70 | 71 | 74 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | 0.00 | 5.47 | 97.53 | 0.00 | 51.56 | ||||
| P/S | — | — | — | — | — | 0.00 | 4.55 | 4.80 | 3.34 | 4.52 | |||||
| P/B | — | — | — | — | — | 4.36 | 2.53 | 2.96 | 3.22 | 5.39 | |||||
| EV/Sales | — | — | — | — | — | 0.00 | 3.68 | 4.04 | 2.76 | 3.91 | |||||
| EV/FCF | — | — | — | — | — | (4.26) | 144.02 | 82.33 | 45.80 | 19.39 | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (22) | (50) | (81) | (158) | (137) | (126) | 6 | 13 | 26 | 138 | ||||
| Capex | 0 | 0 | (5) | (3) | 0 | (20) | 0 | 0 | 0 | (2) | |||||
| Free cash flow | (22) | (50) | (86) | (162) | (137) | (147) | 6 | 13 | 25 | 136 | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 54 | 30 | 271 | 214 | 301 | 152 | 196 | 213 | 231 | 388 | ||||
| Total debt | — | — | — | 3 | 7 | 6 | 6 | — | — | — | |||||
| Net debt | (56) | (46) | (307) | (233) | (324) | (182) | (191) | (206) | (244) | (414) | |||||
| Shareholders’ equity | 54 | 30 | 279 | 225 | 312 | 185 | 396 | 439 | 438 | 568 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (46.12) | (124.80) | (55.88) | (56.16) | (53.44) | (54.24) | 52.96 | 2.86 | (7.80) | 8.78 | ||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (3,451.96) | 2.97 | (6.77) | (14.63) | 31.44 | |||||
| ROE | 41.53 | 112.39 | (108.91) | (64.15) | (60.06) | (63.55) | 63.10 | 3.37 | (9.85) | 11.73 | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
Kiniksa Pharmaceuticals International, plc vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| RDY Dr. Reddy's Laboratories Ltd | $10.7B | 32.9× | 24.3× | −14.44% (below 0%: shrinking) | −70.00% (below 0%: shrinking) | −143.40% (below 0%: shrinking) | 46.54% | 4.81% | Compare |
| HIMS Hims & Hers Health, Inc. | $6.9B | — (loss-making) | — (loss-making) | +38.25% (above 0%: growing) | n/m | +5.09% (above 0%: growing) | 63.83% | (12.90%) | Compare |
| ALKS Alkermes plc | $6.7B | 102× | — (loss-making) | +26.97% (above 0%: growing) | −99.43% (below 0%: shrinking) | +1.13% (above 0%: growing) | 80.22% | 3.70% | Compare |
| LNTH Lantheus Holdings, Inc. | $6.5B | 23.7× | 25.3× | +2.68% (above 0%: growing) | 0.00% | +13.55% (above 0%: growing) | 62.30% | 25.82% | Compare |
| KNSA Kiniksa Pharmaceuticals International, plc | $6.2B | 73.4× | 38.7× | +55.36% (above 0%: growing) | +37.50% (above 0%: growing) | +66.63% (above 0%: growing) | 90.32% | 11.16% | |
| AMRX AMNEAL PHARMACEUTICALS, INC. | $6.2B | 38.4× | 51.6× | +9.89% (above 0%: growing) | +157.14% (above 0%: growing) | −351.41% (below 0%: shrinking) | 42.01% | 16.30% | Compare |
| RGC Regencell Bioscience Holdings Limited | $4.7B | — (loss-making) | — | — | — | +57.15% (above 0%: growing) | 0.00% | — | Compare |
| INDV Indivior Pharmaceuticals Inc. | $4.0B | 11.2× | 11.8× | +13.58% (above 0%: growing) | +580.00% (above 0%: growing) | +58.57% (above 0%: growing) | 85.42% | 46.36% | Compare |
| AMLX Amylyx Pharmaceuticals, Inc. | $3.5B | — (loss-making) | — (loss-making) | −100.61% (below 0%: shrinking) | n/m | −24.50% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| Median of peers | $6.3B | 32.9× | 24.8× | +9.89% | 0.00% | +3.11% | 63.06% | 4.81% |
Kiniksa Pharmaceuticals International, plc (KNSA) key facts
- Strength: Kiniksa Pharmaceuticals International, plc’s revenue for fiscal 2025 (year ended December 2025) was $677.6 million, up 60.1% from fiscal 2024.
- Kiniksa Pharmaceuticals International, plc (KNSA) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
- Net income was $59.0 million, or $0.80 per share (basic), a net margin of 8.71%.
- As of October 16, 2026, KNSA traded at $78.59, a market capitalization of $6.2 billion.
- At that price the stock trades at 73.4× trailing-twelve-month earnings and 7.3× sales.
- Return on equity was 11.7% and debt-to-equity 0.00.
- Its Piotroski F-score is 8 out of 9 and its Altman Z-score is 10.35 (safe zone) for fiscal 2025.
Kiniksa Pharmaceuticals International, plc (KNSA) Latest News
No news at this impact. Lower the threshold for more.